Grandfield & Dodd LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,271 shares of the company’s stock after selling 1,156 shares during the quarter. Johnson & Johnson makes up approximately 1.7% of Grandfield & Dodd LLC’s portfolio, making the stock its 24th biggest position. Grandfield & Dodd LLC’s holdings in Johnson & Johnson were worth $14,323,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. raised its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after acquiring an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $186,000. Taylor Wealth Management Partners grew its position in shares of Johnson & Johnson by 19.8% in the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after acquiring an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $202,000. Institutional investors and hedge funds own 66.06% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/grandfield-dodd-llc-decreases-stake-in-johnson-johnson-jnj.html.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.56 on Friday. Johnson & Johnson has a 1 year low of $109.32 and a 1 year high of $144.35. The stock has a market cap of $374,930.72, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.68 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.41%. Johnson & Johnson’s payout ratio is presently 58.33%.
Several analysts recently issued reports on the company. Citigroup Inc. raised their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a research note on Monday, October 30th. Leerink Swann reiterated an “outperform” rating and set a $165.00 price target (up from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Finally, Stifel Nicolaus lifted their price objective on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $143.70.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.